Expiration Date: July 26, 2017
Media: Internet - based
This activity is designed to update physicians on the data that has been recently presented at major cancer conferences so they can assess and prepare to apply these findings to their clinical practice to improve patient care.
CME Activity Table of Contents
- Rolapitant for Prevention of CINV in Patients With Breast and Gynecologic Cancers
- Phase II Study of Olanzapine 10 mg Versus 5 mg for Cisplatin-Induced Emesis
- Phase III Study of a NK1 Receptor Antagonist Plus Palonosetron With Dexamethasone on Day 1 or Days 1-3 for Highly Emetogenic Chemotherapy
- Ginger for Prevention of CINV Associated With Adriamycin-Cyclophosphamide
- Practice Patterns and Adherence to Antiemesis Guidelines: Results of a Survey of Oncology Nurses
- APF350 Versus Ondansetron With Fosaprepitant Plus Dexamethasone for CINV Induced by Highly Emetogenic Chemotherapy: Exploratory Age and Gender Subgroup Analyses of Data From the Phase III MAGIC Trial
Instructions For This Activity & Receiving Credit
This educational program is directed toward medical oncologists, nurse practitioners, physician assistants, and nurses. Other healthcare professionals involved in the treatment and management of patients with CINV are also invited to participate.
Educational ObjectivesAt the conclusion of this activity, participants should be better prepared to:
- Discuss clinical trial designs and endpoints of noteworthy trials evaluating novel strategies for the management of CINV
- Assess the effectiveness of emerging antiemetic strategies for CINV in the context of evolving treatment standards in the field
- Place into clinical context emerging evidence concerning novel approaches to manage CINV
- Apply clinical trial evidence to practically manage real-world clinical scenarios in the management of breakthrough symptoms, delayed CINV, nausea, and antiemetic regimens for multi-day chemotherapy
Faculty, Staff, and Planners' DisclosuresFaculty
Richard J. Gralla, MD, FACP
Professor of Medicine
Albert Einstein College of Medicine
Jacobi Medical Center
Bronx, New York
Disclosure: Consultant: Merck, Heron, Helsinn, Tesaro
Eric Roeland, MD
Director of Clinical Research in Symptom Intervention
Assistant Clinical Professor of Medicine
UC San Diego Health - La Jolla
La Jolla, CA
Disclosure: Consultant: Helsinn, Heron; Speaker's Bureau: Helsinn, Eisai, Teva.
The staff of PER®, LLC.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Hardware And Software RequirementsSupported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise